Wells Fargo lowered the firm’s price target on UnitedHealth (UNH) to $351 from $677 and keeps an Overweight rating on the shares following another disappointing update from the company. The firm thinks company-specific factors, including mispricing MA, appear more likely than accelerating trend across industry. Return of CEO Stephen Hemsley should improve execution, Wells adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth CEO Transition Amid Financial Uncertainty
- UnitedHealth downgraded to Neutral at BofA amid MA uncertainty
- UnitedHealth downgraded to Neutral from Buy at BofA
- “Time to Buy the Dip” Analysts Remain Bullish on UnitedHealth Stock (UNH) despite Sell-Off
- UnitedHealth downgraded to Market Perform from Strong Buy at Raymond James